The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1613
ISSUE 1613
December 14, 2020
Drugs for Asthma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
December 14, 2020 (Issue: 1613)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed here.
... more
- Expert Panel Working Group of the NHLBI. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146:1217.
- Global Initiative for Asthma. Global strategy for asthma management and prevention (2020 update). Available at www.ginasthma.org. Accessed December 3, 2020.
- K Sumino et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma. J Allergy Clin Immunol Pract 2020; 8:176.
- JK Mukker et al. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. J Pharm Sci 2016; 105:2509.
- HW Kelly et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904.
- PM O’Byrne et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018; 378:1865.
- ED Bateman et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018; 378:1877.
- R Beasley et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019; 380:2020.
- J Hardy et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019; 394:919.
- DM Sobieraj et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018; 319:1485.
- DA Stempel et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med 2016; 375:840.
- WW Busse et al. Combined analysis of asthma safety trials of long-acting β2-agonists. N Engl J Med 2018; 378:2497.
- FDA Drug Safety Communication. December 20, 2017. Available at: www.fda.gov/Drugs/DrugSafety/ucm589587. htm. Accessed December 3, 2020.
- DM Sobieraj et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA 2018; 319:1473.
- KM Kew and K Dahri. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016; 1:CD011721.
- LA Lee et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2020 Sep 9 (epub).
- In brief: Neuropsychiatric events with montelukast. Med Lett Drugs Ther 2020; 62:65.
- KM MacDonald et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol 2019; 15:553.
- Mepolizumab (Nucala) for severe eosinophilic asthma. Med Lett Drugs Ther 2016; 58:11.
- KR Chapman et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy 2019; 74:1716.
- Reslizumab (Cinqair) for severe eosinophilic asthma. Med Lett Drugs Ther 2016; 58:81.
- G Brusselle et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther 2017; 43:39.
- Benralizumab (Fasenra) for severe eosinophilic asthma. Med Lett Drugs Ther 2018; 60:33.
- Dupilumab (Dupixent) for asthma. Med Lett Drugs Ther 2019; 61:6.
- S Wenzel et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388:31.
- M Castro et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 2018; 378:2486.
- KF Rabe et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 2018; 378:2475.
- M Wechsler et al. Dupilumab is well tolerated and shows sustained efficacy in patients with asthma: Liberty Asthma Traverse. 78th Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI); virtual meeting; Nov. 13-15, 2020. Abstract P219.
- K Xu et al. Efficacy of add-on sublingual immunotherapy for adults with asthma: a meta-analysis and systematic review. Ann Allergy Asthma Immunol 2018; 121:186.
- NC Thomson. Recent developments in bronchial thermoplasty for severe asthma. J Asthma Allergy 2019; 12:375.
- PI Bonta et al. Bronchial thermoplasty in severe asthma: best practice recommendations from an expert panel. Respiration 2018; 95:289.
- H Wang et al. Asthma in pregnancy: pathophysiology, diagnosis, whole-course management, and medication safety. Can Respir J 2020; 2020:9046842.
- JA Namazy et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020; 145:528.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian